Amarna Therapeutics, a privately held biotechnology company developing gene therapies for rare and prevalent diseases, including Hemophilia B, has appointed Henk Streefkerk Chief Executive Officer and Medical Director. He succeeds Steen Klysner, who served as CEO for the past three years. Streefkerk has been Amarna’s medical director since mid-2022. Streefkerk has had a career as CMO at several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia. He brings over a decade of experienc...